Metabolic therapy of cardiovascular diseases with propionyl L-carnitine
Canadian Journal of Physiology and Pharmacology · 2026
DOI: 10.1139/cjpp-2025-0241 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2026. Verfasst von Naranjan S Dhalla und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Department of Physiology and Pathophysiology, Max Rady Colle…. Hauptthemen laut MEDLINE: Carnitine, Cardiovascular Diseases.
Abstract (Originalsprache)
Propionyl L-carnitine (PPLC), a short -chain fatty acid derivative of carnitine, has been reported to produce beneficial effects in various cardiovascular diseases such as maladaptive cardiac hypertrophy, heart failure, ischemic heart disease, different types of cardiomyopathies and peripheral artery disease. Although all these cardiovascular diseases have diverse epidemiology and pathophysiology, both clinical and preclinical studies have indicated the role of oxidative stress, Ca2+-handling defects and metabolic abnormalities in their development and progression. In heart failure due to myocardial infarction, treatment with PPLC attenuated the inhibition of Na+-K+ ATPase and Na+-Ca2+ exchange activities. PPLC therapy of animals with diabetic cardiomyopathy improved Ca2+- handling abnormalities in cardiomyocytes by affecting the entry of Ca2+ through sarcolemma and regulating the sarcoplasmic reticular Ca2+- pump activities. The improvement of cardiac function recovery by PPLC treatment in ischemia- reperfused hearts was associated with its ability to antagonize the deleterious effects of palmitoyl L-carnitine on Ca2+-handling proteins. Treatment of peripheral artery disease with PPLC increased blood flow by affecting the vascular endothelium and smooth muscle functions in lower limbs. These observations support the view that PPLC improves cardiovascular function in diseased conditions by promoting mitochondrial metabolism, reducing oxidative stress and preventing Ca2+- handling abnormalities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Department of Physiology and Pathophysiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.
- College of Medicine, Alfaisal University, Riyadh, Kingdom of Saudi Arabia.
ORCID-Profile: Naranjan S Dhalla
Zitieren
APA
Dhalla, N., Kaur, K., Elimban, V., & Ganguly, P. (2026). Metabolic therapy of cardiovascular diseases with propionyl L-carnitine. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2025-0241
Vancouver
Dhalla N, Kaur K, Elimban V, Ganguly P. Metabolic therapy of cardiovascular diseases with propionyl L-carnitine. Canadian Journal of Physiology and Pharmacology. 2026. doi:10.1139/cjpp-2025-0241
BibTeX
@article{Dhalla2026,
author = {Dhalla, Naranjan S and Kaur, Khushman and Elimban, Vijayan and Ganguly, Paul},
title = {Metabolic therapy of cardiovascular diseases with propionyl L-carnitine},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2026},
doi = {10.1139/cjpp-2025-0241}
}
EUVIMED